Trial Search Results

PHIL in the Treatment of Intracranial dAVF.

This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Microvention-Terumo, Inc.

Stanford Investigator(s):

Intervention(s):

  • Device: PHIL® Liquid Embolic System

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Age 22 - 80 years.

   - Subject is willing and capable of complying with all study protocol requirements,
   including specified follow-up period.

   - Subject or authorized legal representative must provide written informed consent prior
   to initiation of any study procedures.

   - Subject has an intracranial dAVF

Exclusion Criteria:

   - Subject having multiple dAVFs to be treated.

   - Subject with a history of life threatening allergy to contrast media (unless treatment
   for allergy is tolerated).

   - Subject has known allergies to dimethylsulfoxide, iodine.

   - Subject is currently participating in another clinical study

   - Female subject is currently pregnant.

   - Subject has co-morbid conditions that may limit survival to less than 24 months.

Ages Eligible for Study

22 Years - 80 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting